Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMRA736)

• Drug Name: SACCHARIN Drug Info
• Synonyms: saccharin; 81-07-2; o-Sulfobenzimide; Saccharine; o-Benzoic sulfimide; Saccharimide; Benzosulfimide; o-Benzosulfimide; Benzoic sulfimide; Benzosulphimide; Saccharinose; Garantose; Saccharinol; Gluside; Saccharin acid; Benzosulfinide; Hermesetas; Saccharol; Sweeta; Saccharin insoluble; Glucid; Benzoic sulphimide; 1,2-Benzisothiazol-3(2H)-one, 1,1-dioxide; Saccharina; Zaharina; Sucrette; Sacarina; Kandiset; Sykose; Saxin; o-Benzoyl sulfimide; Benzo-2-sulphimide; Sucre edulcor; o-Benzoic sulphimide; Benzoylsulfonic Imide; o-Sulfobenzoic acid im

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 5143
  ChEBI ID: CHEBI:32111
  CAS Number: CAS 128-44-9
  TTD Drug ID: DMRA736
  VARIDT Drug ID: DR00801

Molecule-Related Drug Atlas

Drug(s) Targeting Carbonic anhydrase I (CA-I)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[7]
Ethoxzolamide	DMVO4ED	Glaucoma/ocular hypertension	9C61	Approved	[8]
Dichlorphenamide	DMH7IDQ	Chronic glaucoma	9C61.0Z	Approved	[8]
Methazolamide	DM7J2TA	Glaucoma/ocular hypertension	9C61	Approved	[9]
Acetazolamide	DM1AF5U	Absence epilepsy		Approved	[8]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[10]
PARABEN	DMEW5Z8	N. A.	N. A.	Phase 3	[11]
CG-100649	DMIKMA9	Arthritis	FA20	Phase 3	[12]
PHENOL	DM1QSM3	N. A.	N. A.	Phase 2/3	[10]
Coumate	DMVKW0N	Breast cancer	2C60-2C65	Phase 2	[13]

Drug(s) Targeting Carbonic anhydrase XII (CA-XII)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[7]
Sulfamylon	DMIO1K0	Bacterial infection	1A00-1C4Z	Approved	[14]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[10]
PARABEN	DMEW5Z8	N. A.	N. A.	Phase 3	[11]
PHENOL	DM1QSM3	N. A.	N. A.	Phase 2/3	[10]
Coumate	DMVKW0N	Breast cancer	2C60-2C65	Phase 2	[13]
FERULIC ACID	DMJC7NF	Discovery agent	N.A.	Patented	[11]
ELLAGIC ACID	DMX8BS5	Discovery agent	N.A.	Investigative	[11]
COUMARIN	DM0N8ZM	Discovery agent	N.A.	Investigative	[15]
CATECHIN	DMY38SB	Discovery agent	N.A.	Investigative	[10]

Drug(s) Targeting Carbonic anhydrase II (CA-II)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[7]
Sulfamylon	DMIO1K0	Bacterial infection	1A00-1C4Z	Approved	[14]
Dorzolamide	DMA17D0	Ocular hypertension	9C61.01	Approved	[16]
Chlorothiazide	DMLHESP	Chronic heart failure	BD1Z	Approved	[17]
Ethoxzolamide	DMVO4ED	Glaucoma/ocular hypertension	9C61	Approved	[18]
Dichlorphenamide	DMH7IDQ	Chronic glaucoma	9C61.0Z	Approved	[18]
Cyclothiazide	DMJ4AWC	Congestive heart failure	BD10	Approved	[19]
Ethinamate	DMK57GB	Insomnia	7A00-7A0Z	Approved	[20]
Benzthiazide	DMQWZ0H	High blood pressure	BA00	Approved	[21]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[10]

Drug(s) Targeting Carbonic anhydrase (CA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[22]
Sulfamylon	DMIO1K0	Bacterial infection	1A00-1C4Z	Approved	[23]
Quinethazone	DMWCOSR	Hypertension	BA00-BA04	Approved	[24]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[10]
PARABEN	DMEW5Z8	N. A.	N. A.	Phase 3	[11]
PHENOL	DM1QSM3	N. A.	N. A.	Phase 2/3	[10]
Coumate	DMVKW0N	Breast cancer	2C60-2C65	Phase 2	[13]
SULFAMIDE	DMMAS3K	N. A.	N. A.	Phase 1	[25]
FERULIC ACID	DMJC7NF	Discovery agent	N.A.	Patented	[11]
PMID30074415-Compound-21	DM3NPOU	N. A.	N. A.	Patented	[26]

Drug(s) Targeting Carbonic anhydrase IX (CA-IX)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[10]
PARABEN	DMEW5Z8	N. A.	N. A.	Phase 3	[11]
PHENOL	DM1QSM3	N. A.	N. A.	Phase 2/3	[10]
Coumate	DMVKW0N	Breast cancer	2C60-2C65	Phase 2	[13]
INDISULAM	DM9SX6Y	Lymphoma	2A80-2A86	Phase 2	[27]
Girentuximab I-124	DMG3O2Z	Renal cell carcinoma	2C90	Phase 2	[28]
SULFAMIDE	DMMAS3K	N. A.	N. A.	Phase 1	[29]
BAY 79-4620	DM14XQN	Solid tumour/cancer	2A00-2F9Z	Phase 1	[30]
90Y-cG250	DMJR6TC	Solid tumour/cancer	2A00-2F9Z	Phase 1	[31]
FERULIC ACID	DMJC7NF	Discovery agent	N.A.	Patented	[11]

Drug(s) Affected By Taste receptor type 2 member 31 (TAS2R31)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[32]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[33]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[34]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[35]

Drug(s) Affected By Transient receptor potential cation channel subfamily V member 1 (TRPV1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[36]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[37]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[38]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[39]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[40]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[41]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[42]
Menthol	DMG2KW7	Back pain	ME84.Z	Approved	[43]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[44]
Lidocaine	DML4ZOT	Anaesthesia	9A78.6	Approved	[45]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Carbonic anhydrase (CA)	TTUNARX	NOUNIPROTAC	Inhibitor	[2]
Carbonic anhydrase I (CA-I)	TTHQPL7	CAH1_HUMAN	Inhibitor	[3]
Carbonic anhydrase II (CA-II)	TTANPDJ	CAH2_HUMAN	Inhibitor	[3]
Carbonic anhydrase IX (CA-IX)	TT2LVK8	CAH9_HUMAN	Inhibitor	[4]
Carbonic anhydrase XII (CA-XII)	TTSYM0R	CAH12_HUMAN	Inhibitor	[4]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Taste receptor type 2 member 31 (TAS2R31)	OTAI2M1L	T2R31_HUMAN	Gene/Protein Processing	[5]
Transient receptor potential cation channel subfamily V member 1 (TRPV1)	OTHHDR03	TRPV1_HUMAN	Gene/Protein Processing	[6]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5432).
• [2] Carbonic anhydrase inhibitors. Characterization and inhibition studies of the most active beta-carbonic anhydrase from Mycobacterium tuberculosis, ... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6649-54.
• [3] Mutation of Phe91 to Asn in human carbonic anhydrase I unexpectedly enhanced both catalytic activity and affinity for sulfonamide inhibitors. Bioorg Med Chem. 2010 Aug 1;18(15):5498-503.
• [4] Carbonic anhydrase inhibitors: copper(II) complexes of polyamino-polycarboxylamido aromatic/heterocyclic sulfonamides are very potent inhibitors of... Bioorg Med Chem Lett. 2008 Jan 15;18(2):836-41.
• [5] Probenecid inhibits the human bitter taste receptor TAS2R16 and suppresses bitter perception of salicin. PLoS One. 2011;6(5):e20123.
• [6] Artificial sweeteners and salts producing a metallic taste sensation activate TRPV1 receptors. Am J Physiol Regul Integr Comp Physiol. 2007 Aug;293(2):R626-34. doi: 10.1152/ajpregu.00286.2007. Epub 2007 Jun 13.
• [7] Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorg Med Chem. 2008 Aug 1;16(15):7424-8.
• [8] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [9] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2597).
• [10] Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3.
• [11] Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
• [12] Understanding the Dual Inhibition of COX-2 and Carbonic Anhydrase-II by Celecoxib and CG100649 Using Density Functional Theory Calculations and other Molecular Modelling Approaches. Protein Pept Lett. 2015;22(10):903-12.
• [13] Carbonic anhydrase inhibitors. Interaction of the antitumor sulfamate EMD 486019 with twelve mammalian carbonic anhydrase isoforms: Kinetic and X-r... Bioorg Med Chem Lett. 2008 Aug 1;18(15):4282-6.
• [14] Sulfonamide linked neoglycoconjugates--a new class of inhibitors for cancer-associated carbonic anhydrases. J Med Chem. 2010 Apr 8;53(7):2913-26.
• [15] Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
• [16] Carbonic anhydrase inhibitors. Inhibition studies of a coral secretory isoform by sulfonamides. Bioorg Med Chem. 2009 Jul 15;17(14):5054-8.
• [17] Localization of diuretic effects along the loop of Henle: an in vivo microperfusion study in rats. Clin Sci (Lond). 2000 Apr;98(4):481-8.
• [18] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [19] Selective effect of thiazides on the human osteoblast-like cell line MG-63. Kidney Int. 1996 Nov;50(5):1476-82.
• [20] Inhibition of carbonic anhydrases I and II by N-unsubstituted carbamate esters. J Biol Chem. 1992 Dec 15;267(35):25044-50.
• [21] Nature of the inhibition of carbonic anhydrase by acetazolamide and benzthiazide. J Pharmacol Exp Ther. 1961 Mar;131:271-4.
• [22] Carbonic anhydrase inhibitors: Inhibition of the new membrane-associated isoform XV with phenols. Bioorg Med Chem Lett. 2008 Jun 15;18(12):3593-6.
• [23] Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54.
• [24] Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for th... Bioorg Med Chem Lett. 2008 Apr 15;18(8):2567-73.
• [25] Carbonic anhydrase inhibitors: crystallographic and solution binding studies for the interaction of a boron-containing aromatic sulfamide with mamm... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3601-5.
• [26] Carbonic anhydrase inhibitors as antitumor/antimetastatic agents: a patent review (2008-2018).Expert Opin Ther Pat. 2018 Oct;28(10):729-740.
• [27] Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-assoc... Bioorg Med Chem Lett. 2004 Jan 5;14(1):217-23.
• [28] Potential role of (124)I-girentuximab in the presurgical diagnosis of clear-cell renal cell cancer. Biologics. 2012;6:395-407.
• [29] Carbonic anhydrase inhibitors. Inhibition of isozymes I, II, IV, V, and IX with anions isosteric and isoelectronic with sulfate, nitrate, and carbo... Bioorg Med Chem Lett. 2005 Feb 1;15(3):567-71.
• [30] Therapeutic mechanism and efficacy of the antibody-drug conjugate BAY 79-4620 targeting human carbonic anhydrase 9. Mol Cancer Ther. 2012 Feb;11(2):340-9.
• [31] Application of monoclonal antibody G250 recognizing carbonic anhydrase IX in renal cell carcinoma. Int J Mol Sci. 2013 May 29;14(6):11402-23.
• [32] MS4A3-HSP27 target pathway reveals potential for haematopoietic disorder treatment in alimentary toxic aleukia. Cell Biol Toxicol. 2023 Feb;39(1):201-216. doi: 10.1007/s10565-021-09639-4. Epub 2021 Sep 28.
• [33] Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
• [34] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [35] Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
• [36] Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol. 2001 Oct;134(4):845-52. doi: 10.1038/sj.bjp.0704327.
• [37] Comparison of protective effect of ascorbic acid on redox and endocannabinoid systems interactions in in vitro cultured human skin fibroblasts exposed to UV radiation and hydrogen peroxide. Arch Dermatol Res. 2017 May;309(4):285-303. doi: 10.1007/s00403-017-1729-0. Epub 2017 Mar 11.
• [38] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [39] Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
• [40] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [41] Design principles of concentration-dependent transcriptome deviations in drug-exposed differentiating stem cells. Chem Res Toxicol. 2014 Mar 17;27(3):408-20.
• [42] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [43] The anthelminthic drug praziquantel is a selective agonist of the sensory transient receptor potential melastatin type 8 channel. Toxicol Appl Pharmacol. 2017 Dec 1;336:55-65. doi: 10.1016/j.taap.2017.10.012. Epub 2017 Oct 18.
• [44] Expression of vanilloid receptor subtype 1 in cutaneous sensory nerve fibers, mast cells, and epithelial cells of appendage structures. Exp Dermatol. 2004 Mar;13(3):129-39. doi: 10.1111/j.0906-6705.2004.0178.x.
• [45] The vanilloid receptor TRPV1 is activated and sensitized by local anesthetics in rodent sensory neurons. J Clin Invest. 2008 Feb;118(2):763-76. doi: 10.1172/JCI32751.